HUP1300646A2 - Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them - Google Patents

Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them

Info

Publication number
HUP1300646A2
HUP1300646A2 HU1300646A HUP1300646A HUP1300646A2 HU P1300646 A2 HUP1300646 A2 HU P1300646A2 HU 1300646 A HU1300646 A HU 1300646A HU P1300646 A HUP1300646 A HU P1300646A HU P1300646 A2 HUP1300646 A2 HU P1300646A2
Authority
HU
Hungary
Prior art keywords
fulvestrant
complexes
derivatives
preparation
pharmaceutical compositions
Prior art date
Application number
HU1300646A
Other languages
English (en)
Inventor
Erzsebet Reka Angi
Tamas Solymosi
Richard Balazs Karpati
Zsofia Fenyvesi
Zsolt Oetvoes
Laszlo Molnar
Hristos Glavinas
Genoveva Filipcsei
Katalin Ferenczi
Gabor Heltovics
Original Assignee
Druggability Technologies Ip Holdco Jersey Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Druggability Technologies Ip Holdco Jersey Ltd filed Critical Druggability Technologies Ip Holdco Jersey Ltd
Priority to HU1300646A priority Critical patent/HUP1300646A2/hu
Priority to US14/538,184 priority patent/US20150132388A1/en
Priority to ARP140104246A priority patent/AR098389A1/es
Priority to EP14808728.1A priority patent/EP3068377A1/en
Priority to PCT/IB2014/065986 priority patent/WO2015071836A1/en
Priority to TW103139255A priority patent/TW201540303A/zh
Publication of HUP1300646A2 publication Critical patent/HUP1300646A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HU1300646A 2013-11-12 2013-11-12 Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them HUP1300646A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
HU1300646A HUP1300646A2 (en) 2013-11-12 2013-11-12 Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US14/538,184 US20150132388A1 (en) 2013-11-12 2014-11-11 Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
ARP140104246A AR098389A1 (es) 2013-11-12 2014-11-11 Complejos de fulvestrant y sus derivados, proceso para su preparación y composiciones farmacéuticas que los contienen
EP14808728.1A EP3068377A1 (en) 2013-11-12 2014-11-12 Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
PCT/IB2014/065986 WO2015071836A1 (en) 2013-11-12 2014-11-12 Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
TW103139255A TW201540303A (zh) 2013-11-12 2014-11-12 法洛德及其衍生物的錯合物、製備製程以及藥品組合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU1300646A HUP1300646A2 (en) 2013-11-12 2013-11-12 Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
HUP1300646A2 true HUP1300646A2 (en) 2015-05-28

Family

ID=89991320

Family Applications (1)

Application Number Title Priority Date Filing Date
HU1300646A HUP1300646A2 (en) 2013-11-12 2013-11-12 Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them

Country Status (6)

Country Link
US (1) US20150132388A1 (hu)
EP (1) EP3068377A1 (hu)
AR (1) AR098389A1 (hu)
HU (1) HUP1300646A2 (hu)
TW (1) TW201540303A (hu)
WO (1) WO2015071836A1 (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP1600270A2 (hu) * 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Ivacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadott készítményei
HUP1600271A2 (hu) * 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei
US10383865B2 (en) 2016-04-25 2019-08-20 Druggability Technologies Ip Holdco Limited Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
HUP1600269A2 (hu) * 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Lumacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyászati készítményei
US10376501B2 (en) 2016-04-25 2019-08-13 Druggability Technologies Ip Holdco Limited Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US10206915B2 (en) 2016-04-25 2019-02-19 Druggability Technologies Ip Holdco Limited Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
CN116832020A (zh) 2017-09-11 2023-10-03 阿托萨治疗学公司 制备和使用内昔芬的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0210867A (pt) * 2001-07-06 2004-06-29 Lifecycle Pharma As Processo para a preparação de um material particulado, métodos para aglomeração controlada de um material sólido finamente disperso, para melhorar a biodisponibilidade de uma substância terapêutica e/ou profilaticamente ativa, e para melhorar a vida em prateleira de uma composição farmacêutica, material articulado, composição farmacêutica, uso de um veìculo, material particulado farmacêutico, e, uso de aluminossilicato de magnésio e/ou de aluminometassilicato de magnésio
EP1660227B1 (en) * 2003-08-04 2012-05-23 Camurus Ab Method for improving the properties of amphiphile particles
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
SG165404A1 (en) * 2005-09-26 2010-10-28 Hospira Australia Pty Ltd Fulvestrant formulation
RS20080167A (en) 2005-10-21 2009-07-15 Panacea Biotec Limited, Novel improved compositions for cancer therapy
WO2008060899A2 (en) * 2006-11-09 2008-05-22 Ore Pharmaceuticals Inc. Breast cancer screening and treatment methods
US7687487B2 (en) * 2007-04-19 2010-03-30 Bionumerik Pharmaceuticals, Inc. Camptothecin-analog with a novel, “flipped” lactone-stable, E-ring and methods for making and using same
SI2200588T1 (sl) 2007-09-25 2019-08-30 Solubest Ltd. Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo
JP2011514349A (ja) 2008-03-07 2011-05-06 サイドース・エルエルシー フルベストラント配合物
HU230862B1 (hu) 2008-04-28 2018-10-29 DARHOLDING Vagyonkezelő Kft Berendezés és eljárás nanorészecskék folyamatos üzemű előállítására
US8586092B2 (en) * 2009-08-31 2013-11-19 Xi'an Libang Pharmaceutical Technology Co., Ltd. Fulvestrant nanosphere/microsphere and preparative method and use thereof
EA201300341A1 (ru) 2010-09-16 2013-09-30 Шимода Байотек (Пти) Лтд. Композиция фулвестранта и способы применения
CA2836831C (en) 2011-05-20 2015-06-02 Capital, Business Y Gestion De Finanzas S.L. Pharmaceutical composition
SG11201403714TA (en) * 2011-12-30 2014-07-30 Halozyme Inc Ph20 polypeptide variants, formulations and uses thereof
CN102600064A (zh) 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法

Also Published As

Publication number Publication date
TW201540303A (zh) 2015-11-01
AR098389A1 (es) 2016-05-26
EP3068377A1 (en) 2016-09-21
WO2015071836A1 (en) 2015-05-21
US20150132388A1 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
HK1231416A1 (zh) 西羅莫司及其衍生物的絡合物、其製備方法以及含有其的藥物組合物
IL240290B (en) History of pyridazinone-amide and pharmaceutical preparations containing them
HK1246189B (zh) 醋酸阿比特龍複合物、其製備方法及包含它們的藥物組合物
HK1223360A1 (zh) 新的吲嗪化合物、其製備方法和包含它們的藥物組合物
EP2978420A4 (en) STABLE NANOCOMPOSITION COMPRISING PACLITAXEL, PROCESS FOR ITS PREPARATION, USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
EP2978423A4 (en) STABLE NANO COMPOSITION WITH DOXORUBICIN, PROCESS FOR THE PREPARATION THEREOF, THE USE THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH
HUP1300646A2 (en) Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HK1211021A1 (en) 2-substituted-6-biarylmethylamino-9-cyclopentyl-9h-purine derivatives, use thereof as medicaments, and pharmaceutical compositions 2--6--9--9h-
IL246406A0 (en) History of imidazopyrazinone, their preparation and pharmaceutical preparations containing them
HUP1300647A2 (hu) Ciklosporin A és származékainak komplexei, elõállításuk és gyógyszerészeti kompozícióik
HUP1500618A2 (en) Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them
IL243227B (en) History of diaminocyclopentane carboxamide, their preparation and pharmaceutical preparations containing them
EP2941418A4 (en) N1-CYCLIC AMIN-N5 SUBSTITUTED BIGUANIDE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION THEREWITH
EP2978428A4 (en) STABLE NANO COMPOSITION WITH EPIRUBICIN, PROCESS FOR THE PRODUCTION THEREOF, THE USE THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH
EP2978421A4 (en) STABLE NANOCOMPOSITION COMPRISING DOCATEXEL, PROCESS FOR PREPARATION THEREOF, USE THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
IL243223B (en) History of imidazole, their preparation and pharmaceutical preparations containing them
IL246297A0 (en) History of pyrazine, their preparation and pharmaceutical preparations containing them
IL239873A0 (en) The history of piperidinylcarbazole, their preparation and pharmaceutical preparations containing them
IL243012B (en) History of hydroxy-ethylene, their preparation and pharmaceutical preparations containing them
IL244102A0 (en) The history of cyclopentylamine, their preparation and pharmaceutical preparations containing them
IL262490A (en) Lomacaptor complexes and their salts and derivatives, a process for their preparation and pharmaceutical preparations containing them
IL262489A (en) Complexes of ivacaptor and its salts and their history, a process for their preparation and pharmaceutical preparations containing them
HUP1300648A2 (hu) Dabigatran és származékainak komplexei,elõállításuk és gyógyszerészeti kompozícióik
HUP1400084A2 (hu) Dabigatran és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
HUP1300393A2 (en) Quinazoline derivatives, process for the preparation thereof and pharmaceutical compositions comprising the same

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: DRUGGABILITY TECHNOLOGIES IP HOLDCO LIMITED, MT

Free format text: FORMER OWNER(S): DRUGGABILITY TECHNOLOGIES IP HOLDCO (JERSEY) LIMITED, JE

FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished